[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infections-utis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infections-utis":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100644961","interest-of-the-negative-predictive-value-of-integrons-in-the-reduction-of-large-broad-spectrum-antibiotics-consumption-for-urinary-tract-infections-100644961",false,"NCT07675018","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS","INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS: a Randomized Trial","INVICTUS","Inclusion Criteria:\n\n* Age ≥ 18 years old; Hospitalized or admitted to the Emergency department;\n* Diagnosis of non-severe (qSOFA \\\u003C 2) urinary tract infection coupled with fever ≥ 38°C or \\\u003C 36°C\n* Presence of bacteria in the fresh urine sample and\u002For GNB on the Gram stain\n* Empirical parenteral antibiotic therapy required; Hospitalization required;\n* Former documentation of a 3GC-resistant GNB on a microbiological sample in the previous six months\n* Informed consent of the patient or their representative\n\nExclusion Criteria:\n\n* Pregnant and\u002For breastfeeding\n* Neutropenia (absolute neutrophil count \\\u003C 500 \u002F mm3)\n* Severe UTI with sepsis (qSOFA ≥ 2) or septic shock\n* Urinary derivation required (ureteral catheter\u002Fper-cutaneous nephrostomy) except for simple urinary catheterization\n* Known allergy to β-lactams\n* Patients with a former documentation with carbapenemase-producing Enterobacterales in the last 6 months\n* Ongoing antibiotic treatment with 3GC, piperacillin-tazobactam or carbapenem\n* Not affiliated to Social Security","ALL","18 Years",{"count":20,"type":21},204,"ESTIMATED","INTERVENTIONAL",[24],"NA","Urinary tract infections (UTI), mainly driven by Gram-negative bacteria (GNB) are a frequent cause of hospitalization and the second cause of antibiotic prescription after lower respiratory tract infections. Integrons play a major role in the dissemination of antibiotic resistance among GNB. In the prospective INVICTUS project, whose ultimate objective is to reduce the use of large broad-spectrum antibiotics, our hypothesis is that, in adult patients with a non-severe UTI (qSOFA\\\u003C2) and a former documentation with a 3GC-resistant GNB in the previous 6 months, integrons search could reduce the empirical use of large broad-spectrum antibiotics.",[27,28,29,30],"Drug Resistance, Microbial","Biomarkers","Urinary Tract Infections (UTI's)","Antibacterial Agents",[32,33,34,35],"Integron","Antimicrobial Stewardship","Antimicrobial Resistance","Urinary Tract Infections","NOT_YET_RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":21},"2026-09-15",{"date":44,"type":21},"2028-09-21",{"name":46,"class":47},"University Hospital, Limoges","OTHER",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100630044","antibiofilm-activity-of-chitosan-nanoparticles-against-uropathogenic-escherichia-coli-100630044","NCT07482553","Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli","Evaluation of the Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli Isolated From Assiut University Hospitals","Inclusion Criteria:\n\n* 1\\. Patients (inpatients or outpatients) clinically diagnosed with urinary tract infection (UTI).\n\n  2\\. Presence of significant bacteriuria in urine culture (≥10⁵ colony-forming units per milliliter (CFU\u002FmL) for midstream urine, or as clinically indicated).\n\n  3\\. Isolation of Escherichia coli as the sole or predominant pathogen from urine culture.\n\n  4\\. Patients of any age and both sexes. 5. Patients who have not received antibiotic therapy within the previous 48-72 hours.\n\nExclusion Criteria:\n\n* 1\\. Patients who received systemic antibiotic therapy within the previous 48-72 hours prior to urine sample collection.\n\n  2\\. Urine cultures showing insignificant bacteriuria (\\\u003C10⁵ CFU\u002FmL for midstream urine, unless clinically justified).\n\n  3\\. Polymicrobial growth in urine culture (mixed bacterial growth suggestive of contamination).\n\n  4\\. Isolation of organisms other than Escherichia coli. 5. Improperly collected, leaking, or contaminated urine samples. 6. Patients unwilling to provide informed consent.",{"count":57,"type":21},60,"OBSERVATIONAL","1. Isolation of uropathogenic Escherichia coli (UPEC) and determination of their Antimicrobial sensitivity Patterns.\n2. Evaluation of biofilm-forming capacity of UPEC isolates.\n3. Assessment of the antibiofilm efficacy of chitosan nanoparticles alone and in combination with ciprofloxacin against UPEC isolates.\n4. Examination of the effectiveness of chitosan nanoparticle coating in preventing biofilm formation by UPEC on urinary catheter surfaces.\n5. Evaluation of the impact of chitosan nanoparticles on the expression levels of biofilm associated genes in UPEC.",[61,62,63],"Urinary Tract Infections (UTIs)","Catheter-Associated Urinary Tract Infections (CAUTIs)","Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)",[65,66,67,68,69,70,71,72],"Uropathogenic Escherichia coli (UPEC)","Biofilm","Chitosan Nanoparticles","Ciprofloxacin","Catheter-Associated Urinary Tract Infection (CAUTI)","Antibiofilm Activity","Urinary Catheter Biofilm","quantitative real-time polymerase chain reaction (qRT-PCR) gene expression","2026-03-23",{"date":75,"type":40},"2026-03-27",{"date":77,"type":21},"2026-05-01",{"date":79,"type":21},"2027-06",{"name":81,"class":47},"Assiut University",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":82},"100610891","evaluation-of-the-effectiveness-and-safety-of-a-vaginal-gel-for-prevention-of-recurrent-urinary-tract-infections-100610891","NCT07233473","Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections","Prospective, Multicentric, Single Arm Clinical Investigation to Assess the Effectiveness and Safety of Multi-Gyn UT Protect Gel for Prevention of Recurrent Urinary Tract Infections","UTI","Inclusion Criteria:\n\n1. Age: 18 to 84 years old.\n2. Sex: Female.\n3. Subject suffering from uncomplicated recurrent urinary tract infections: ≥ 4. UTIs within 12 months or ≥ 2 within 6 months.\n4. Subject having given freely and expressly her informed consent.\n5. Subject using a contraceptive regimen recognized as effective (pill, implant, Intra Uterine Device (IUD), condoms) since at least 12 weeks before inclusion visit and during the whole study. If subject use condoms as contraceptive regimen, a delay of 6 hours between application and sexual intercourse must be respected.\n6. Subject affiliated to a health social security system.\n7. Subject cooperative and aware of the device's modalities of use and the necessity and duration of the follow-up visits so that perfect adhesion to the protocol can be expected.\n\nExclusion Criteria:\n\n1. Pregnant or nursing woman or planning a pregnancy during the study.\n2. Subject who gave birth in the 3 previous months.\n3. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.\n4. Subject in a social or sanitary establishment.\n5. Subject suspected to be non-compliant according to the investigator's judgment.\n6. Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study.\n7. Subject enrolled in another clinical trial or which exclusion period is not over.\n8. Subject with history of complicated urinary tract infection.\n9. Subject with urinary tract infection at the time of inclusion.\n10. Subject with vaginal mycosis infection in the last 3 weeks.\n11. Subject with recurrent vaginal mycosis (more than 2 in the last 6 months).\n12. Subject having a known allergy or hypersensitivity to one of the components of the investigational device.\n13. Subject suffering from a sexually transmitted gynaecological infection or aerobic vaginitis (including gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis).\n14. Subject with history of hormone-dependent cancer or bladder cancer.\n15. Subject with current genital malignancies.\n16. Subject who had a chemotherapy treatment for a cancer in the 12 months before inclusion.\n17. Subject who had a radiotherapy treatment in the genito-urinary area in the 12 months before inclusion.\n18. Subject using treatment for urinary tract infection, vaginal conditions, vaginal infections, or other intravaginal treatment at the time of inclusion.\n19. Subject using food supplements for prevention of urinary tract infection in the last 3 months.\n20. Subject using antibiotics, corticoids or antifungal treatment for any reason in the 3 weeks before inclusion.\n21. Subject using vaginal douches and who do not wish to refrain using them during the clinical investigation.\n22. Subject with a pessary.\n23. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.",true,"FEMALE","84 Years",{"count":95,"type":21},50,[24],"Urinary Tract Infections (UTIs) are among the most common bacterial infections. Although they are typically treated effectively with antibiotics, recurrence is a frequent and troublesome issue.\n\nThis clinical trial aims to evaluate the safety and effectiveness of Multi-Gyn UT Protect gel in preventing the recurrence of UTIs. The trial will involve 50 adult female participants who have experienced a UTI in recent months but do not currently have an active infection.\n\nEach participant will apply the gel twice a week for four months. They will be monitored throughout this period to assess whether participants develop the reappearance of UTI symptoms.\n\nThe primary objective is to determine how many participants do not experience a recurrence of UTI by the end of the four-month treatment period.",[61],"RECRUITING","2025-11-25",{"date":102,"type":40},"2025-12-03",{"date":104,"type":40},"2025-10-20",{"date":106,"type":21},"2027-03-31",{"name":108,"class":109},"Karo Pharma AB","INDUSTRY"]